Today, Lung Cancer Alliance (LCA) announced that its efforts to secure increased federal research funding for lung cancer achieved another victory as an additional $12.8 million was included in the Department of Defense (DOD) Congressionally Directed Medical Research Program (CDMRP) which was part of the FY2011 budget compromise approved by Congress. The President is expected to sign it into law tonight.
The FY2011 budget compromise plan reduces federal agency budgets by $38 billion and averted a government shutdown.
The $12.8 million in research funding is in addition to $35 million secured to date by LCA since it first established the DOD lung cancer research pipeline in 2009 which targets research for early detection with special emphasis on high risk military.
"We are proud to share that to date we have secured $47.8 million for lung cancer research funding via this investigative pipeline," said Laurie Fenton-Ambrose, President and CEO of LCA. This has been the focus of our core mission from day one and we will continue these efforts for patients and survivors as well as our research community. I thank our congressional leadership for understanding the need and electing to continue support for this program. "
Lung cancer is the leading cause of cancer death among men and women and every ethnic group and among our military who are at an increased risk in comparison to their civilian counterparts. Lung cancer has a 15% 5-year survival rate with the vast majority of cases found late stage. In addition, 80% of those diagnosed with lung cancer today are former or non-smokers.
Triple-negative breast cancer patients with high immune cell levels have lower relapse risk after surgery